Top Tweets for #CETPi

about 1 year ago

@JohnKastelein @DrDerekConnolly @TIMIStudyGroup @ProfKausikRay Let’s see with #Obicetrapib as a #CETPi what will be the magnitude of benefits on #MACE ☀️

0

3

0

114

about 1 year ago

#Obicetrapib the new #LLT to follow #CETPi

NEJM

@NEJM

about 1 year ago

In the BROADWAY trial involving patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days. Full trial results and Research Summary: https://t.co/YHt2m5JYeU

NEJM's tweet photo. In the BROADWAY trial involving patients at high cardiovascular risk, the cholesteryl ester transfer protein inhibitor obicetrapib reduced low-density lipoprotein cholesterol levels by 29.9% at 84 days. Full trial results and Research Summary: https://t.co/YHt2m5JYeU https://t.co/hiaEfsMVeK

3

52

15

3

13K

2

18

5

3

2K

over 1 year ago

Recent advances in immunotherapy targeting #CETPi for #atherosclerosis prevention https://t.co/7y9DLJ0bRb

1

13

3

1

568

about 3 years ago

An article published in @ehj_ed advocates that patients at very high risk for #CVD start combination lipid-lowering therapy as a first-line strategy. Data from our ROSE trial show our #CETPi may be a potent adjunct to high-intensity statin therapy. https://t.co/nGqj2WL0Rw

NewAmsPharma's tweet photo. An article published in @ehj_ed advocates that patients at very high risk for #CVD start combination lipid-lowering therapy as a first-line strategy. Data from our ROSE trial show our #CETPi may be a potent adjunct to high-intensity statin therapy. https://t.co/nGqj2WL0Rw https://t.co/8JBnUZmBaW

0

5

0

292

cardio-met

@cardiomet_CE

over 3 years ago

34b) It’s c, #PCSK9i. That’s a bit of a trick question, as #CETPi does appear to lower Lp(a) levels, but to date has not been associated with event reduction.

1

4

1

0

1K

over 3 years ago

Last field in which #CETPi may play a role : sepsis. Interesting session by J Kastelein at #EASCongress2023

0

11

1

0

919

over 3 years ago

Dry #AMD and #CETPi at #EASCongress2023 by J Kastelein.

0

7

1

0

868

over 3 years ago

#CETPi reduces the incidence of #T2D as highlighted by J Kastelein at #EASCongress2023

1

14

1

0

1K

over 3 years ago

#CETPi #ApoE and potential benefits in Alzheimer’s disease (AD) explained by J.Kastelein atEASCongress2023

2

12

1

0

904

over 3 years ago

#EASCongress2023 session on #CETPi a summary of REVEAL TULIP and ROSE studies by J.Kastelein.

0

18

3

0

4K

over 3 years ago

#EASCongress2023 nice session about #CETPi with ⁦@JohnKastelein⁩ explaining the development on these agents and CV benefits mainly linked to #ApoB decrease.

SABOURETCardio's tweet photo. #EASCongress2023 nice session about #CETPi with ⁦@JohnKastelein⁩ explaining the development on these agents and CV benefits mainly linked to #ApoB decrease. https://t.co/53EiJnCB0k

0

6

0

558

over 3 years ago

We're investigating obicetrapib, a #CETPi, as an LDL-c lowering therapy for high-risk #CVD patients who are unable to meet their treatment goals. We believe by potently lowering 'bad' cholesterol, we can help patients hit their targets. https://t.co/CWenHjzRky

0

12

6

1

1K

over 3 years ago

Our Chief Scientific Officer, @johnkastelein, joined @AlainBouchard for a @myheartnet podcast exploring the benefits of combination therapy for LDL lowering in #ASCVD. Learn how a new mechanism, #CETPi, is showing promise across multiple trials. https://t.co/l9ZNnKfV1H

0

12

0

7

7K

over 3 years ago

Compare these figures to the latest data from our Phase 2b trials evaluating our #CETPi on top of high-intensity statin therapy. ROSE2 saw a median 59% ⬇️ in LDL-c with the obicetrapib + ezetimibe combination, plus favorable safety & tolerability. https://t.co/FpqPhKN4ei

NewAmsPharma's tweet photo. Compare these figures to the latest data from our Phase 2b trials evaluating our #CETPi on top of high-intensity statin therapy. ROSE2 saw a median 59% ⬇️ in LDL-c with the obicetrapib + ezetimibe combination, plus favorable safety & tolerability. https://t.co/FpqPhKN4ei https://t.co/i9f0B5J1oI

0

8

0

2

668

over 3 years ago

According to a meta-analysis published in the European Heart Journal, #CETP inhibitors are associated with a 16% ⬇ risk of new-onset #diabetes, & with better glycemic control. We're investigating our #CETPi to determine if it can produce similar results. https://t.co/K3QtvZd0zl

NewAmsPharma's tweet photo. According to a meta-analysis published in the European Heart Journal, #CETP inhibitors are associated with a 16% ⬇ risk of new-onset #diabetes, & with better glycemic control. We're investigating our #CETPi to determine if it can produce similar results. https://t.co/K3QtvZd0zl https://t.co/ZhxFHKaefM

0

8

0

308

over 3 years ago

This American #HeartMonth, we continue development of our #CETPi, obicetrapib -- with the goal of delivering a simple, oral and potent LDL-lowering treatment for the many millions of patients not achieving their LDL goals. https://t.co/JTYmPCMfui

NewAmsPharma's tweet photo. This American #HeartMonth, we continue development of our #CETPi, obicetrapib -- with the goal of delivering a simple, oral and potent LDL-lowering treatment for the many millions of patients not achieving their LDL goals. https://t.co/JTYmPCMfui https://t.co/rnj8yInUjW

0

3

0

282